AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 152 filers reported holding AKERO THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 1.85 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,580,240 | +25.3% | 70,784 | +15.7% | 0.00% | +33.3% |
| Q2 2023 | $2,856,214 | +135975.0% | 61,174 | +11.5% | 0.00% | 0.0% |
| Q1 2023 | $2,099 | -25.9% | 54,871 | +6.1% | 0.00% | -25.0% |
| Q4 2022 | $2,834 | -99.8% | 51,713 | +22.4% | 0.00% | +100.0% |
| Q3 2022 | $1,439,000 | +284.8% | 42,261 | +6.8% | 0.00% | +100.0% |
| Q2 2022 | $374,000 | -0.3% | 39,586 | +49.8% | 0.00% | – |
| Q1 2022 | $375,000 | -30.9% | 26,420 | +3.0% | 0.00% | -100.0% |
| Q4 2021 | $543,000 | -7.3% | 25,655 | -2.1% | 0.00% | 0.0% |
| Q3 2021 | $586,000 | -5.6% | 26,201 | +4.7% | 0.00% | 0.0% |
| Q2 2021 | $621,000 | +56.8% | 25,026 | +83.3% | 0.00% | 0.0% |
| Q1 2021 | $396,000 | +6.5% | 13,650 | -5.2% | 0.00% | 0.0% |
| Q4 2020 | $372,000 | -7.9% | 14,400 | +9.7% | 0.00% | 0.0% |
| Q3 2020 | $404,000 | +41.8% | 13,130 | +14.7% | 0.00% | – |
| Q2 2020 | $285,000 | – | 11,446 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $169,134,000 | 18.83% |
| venBio Partners LLC | 2,444,311 | $70,909,000 | 6.74% |
| Versant Venture Management, LLC | 617,727 | $17,920,000 | 3.49% |
| Redmile Group, LLC | 2,513,746 | $72,924,000 | 1.03% |
| Boxer Capital, LLC | 831,495 | $24,122,000 | 0.82% |
| Integral Health Asset Management, LLC | 85,000 | $2,466,000 | 0.70% |
| Vivo Capital, LLC | 673,280 | $19,532,000 | 0.69% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 32,000 | $928,000 | 0.51% |
| Cormorant Asset Management, LP | 742,549 | $21,541,000 | 0.48% |
| HHLR ADVISORS, LTD. | 1,656,673 | $48,060,000 | 0.48% |